Nearly every substance that produces a noticeable shift in mood or pain perception interacts with your body’s endorphin system in some way, though the mechanisms vary enormously. Opioids like morphine and fentanyl bind directly to the same receptors that endorphins use. Alcohol triggers a measurable spike in endorphin release at moderate doses. Nicotine, cocaine, cannabis, and even ketamine all leave fingerprints on the endorphin pathway, sometimes boosting it, sometimes suppressing it, and sometimes doing both depending on dose and timing. What makes this topic genuinely tricky is that most of these drugs don’t simply “raise” or “lower” endorphins in a clean, predictable way.
How Opioid Drugs Hijack the Endorphin System
Your body produces its own painkillers, the best known being beta-endorphin. These molecules bind to opioid receptors, especially the mu opioid receptor, to dampen pain signals and produce feelings of well-being. Prescription and illicit opioids, including morphine, oxycodone, heroin, and fentanyl, work because they fit into the same receptor that your natural endorphins activate. Structural studies show that both morphine-type and fentanyl-type molecules form a key chemical bond with the same amino acid deep in the mu receptor’s binding pocket, which is the universal docking point for opioid and related ligands.1Cell. Structures of the human μ-opioid receptor bound to morphinan and fentanyl analogs That shared mechanism is why synthetic opioids can so effectively mimic and overpower the subtle signal your endorphins send.
The problem is what happens next. When you flood those receptors with a potent external opioid day after day, the brain dials down its own production. Chronic morphine exposure reduces expression of the precursor protein that the body uses to make beta-endorphin and also decreases the density of mu opioid receptors on the neurons that produce endorphins.2Frontiers in Systems Neuroscience. Endogenous opioid systems alterations in pain and opioid use disorder On top of that, repeated receptor activation leads to desensitization and internalization of the receptors themselves. The net result is a system that makes fewer endorphins and has fewer working receptors to catch whatever endorphins remain. That downward spiral contributes to tolerance, meaning you need more drug to feel the same effect, and to the heightened pain sensitivity and emotional misery that characterize opioid withdrawal. In practical terms, long-term opioid use doesn’t just borrow from the endorphin system; it degrades its infrastructure.
Alcohol and Endorphins
Alcohol’s relationship with endorphins is more nuanced than the opioid story. Rather than directly binding opioid receptors, alcohol triggers the brain to release its own endorphins. Research measuring beta-endorphin levels in the midbrain after ethanol exposure found a biphasic pattern: low to moderate doses of alcohol caused a significant increase in beta-endorphin release, while higher doses did not produce the same rise.3PubMed Central. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area That finding maps onto what many drinkers experience intuitively: the first drink or two feels rewarding, but pounding more drinks past a certain point doesn’t multiply the pleasant buzz in a linear way.
This endorphin link is central to why certain medications help people cut back on drinking. Naltrexone, a competitive antagonist at the mu opioid receptor, blocks the receptor so that the endorphin surge alcohol provokes doesn’t translate into pleasure the way it normally would.4PubMed. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence In controlled settings, naltrexone reduces both the desire to drink and the amount of alcohol consumed in people with alcohol dependence.5PubMed. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis The logic is straightforward: if the endorphin reward is what keeps you reaching for another glass, blocking the receptor dampens that loop. It doesn’t eliminate all of alcohol’s effects, since alcohol acts on many neurotransmitter systems simultaneously, but the endorphin piece appears to be one of the main drivers of its reinforcing pull.
Nicotine
Nicotine’s effect on endorphins follows a pattern that repeats across several addictive substances: a brief spike followed by long-term depletion. In cell culture, acute nicotine exposure stimulates hypothalamic neurons to secrete beta-endorphin. But after about 24 hours of continuous nicotine, those neurons stop responding, a desensitization that suggests the system is already adapting.6Life Sciences. The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal What’s particularly interesting is what happens after nicotine is removed: beta-endorphin secretion rebounds and stays elevated for about 72 hours after withdrawal. That rebound may partly explain the restlessness and irritability of quitting smoking, as well as the strangely positive feelings some people report a few days in.
In whole-animal studies, both short-term and prolonged nicotine treatment lowered beta-endorphin content in the hypothalamus and in downstream brain regions like the striatum and hippocampus.7PubMed. Nicotine-induced changes of brain β-endorphin That drop was reversed by nicotinic receptor blockers and by dopamine receptor blockers, indicating that nicotine’s endorphin effects involve dopamine circuitry as well. The takeaway is that smoking doesn’t just act through nicotinic receptors in isolation; it reshapes endorphin signaling across multiple brain circuits, and the changes are tied up with the same dopamine pathways implicated in other forms of addiction.
Cocaine and Other Stimulants
Stimulants like cocaine and amphetamine are best known for slamming the dopamine system, but they also rearrange the brain’s opioid peptide machinery in ways that likely contribute to craving and compulsive use. After repeated cocaine self-administration in rats, the mRNA for two endogenous opioid precursors, proenkephalin and prodynorphin, went up in the dorsal striatum, while the mRNA for proopiomelancortin, the precursor for beta-endorphin, was essentially wiped out in the same region.8PubMed Central. Cocaine Self-administration Regulates Transcription of Opioid Peptide Precursors and Opioid Receptors in Rat Caudate Putamen and Prefrontal Cortex In the prefrontal cortex, only prodynorphin went up, while beta-endorphin precursor levels stayed unchanged. The picture is one of selective disruption rather than a simple system-wide boost or crash.
Even a single dose of cocaine or a similar dopamine reuptake blocker can acutely elevate the mRNA for enkephalin, dynorphin, and substance P in the striatum, with the biggest changes appearing within a couple of hours.9Molecular Brain Research. Influence of a single injection of cocaine, amphetamine or GBR 12909 on mRNA expression of striatal neuropeptides Amphetamine was more selective, boosting substance P but not the opioid peptides to the same degree. These findings suggest that different stimulants don’t have identical effects on the endorphin family, and that cocaine in particular may recruit opioid peptide systems more aggressively than amphetamine. How much of cocaine’s subjective reward depends on this opioid involvement, versus its well-known dopamine effects, remains an active area of research.
Cannabis and the Opioid-Endocannabinoid Crosstalk
The endorphin system and the endocannabinoid system are not independent circuits. They overlap in brain areas involved with processing pain, and their receptors often sit on the same neurons. THC, the primary psychoactive component in cannabis, triggers the release of endogenous opioids, and the body’s own endocannabinoids like anandamide also alter endogenous opioid tone.10PubMed Central. Interaction of the cannabinoid and opioid systems in the modulation of nociception This crosstalk is one reason cannabis can reduce pain perception in ways that go beyond what the endocannabinoid system alone would predict. It’s also part of why some researchers have explored combining low-dose opioids with cannabinoids for pain management, reasoning that the two systems could enhance each other at doses too low to produce the dangerous side effects of either drug alone.
For the casual cannabis user, the practical implication is that the “warm glow” or pain relief from marijuana is partially an endorphin-mediated experience, not purely a cannabinoid one. Whether chronic, heavy cannabis use eventually degrades endorphin function the way chronic opioid use does is less established, and the research is still catching up to the rapid legalization of cannabis across many regions.
Ketamine’s Surprising Opioid Connection
Ketamine is classified as a dissociative anesthetic and is increasingly used to treat severe depression. Its primary known mechanism involves blocking NMDA glutamate receptors. But a striking finding has emerged: when researchers gave people naltrexone (the opioid receptor blocker) before a ketamine infusion for depression, the antidepressant effect was dramatically reduced. Depression scores dropped by about 22 points on a standard scale with ketamine alone, compared with only about 6 points when naltrexone was on board, a significant attenuation.11PubMed Central. Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine Follow-up work confirmed the pattern and extended it to ketamine’s anti-suicidal effects as well.12PubMed Central. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
This does not mean ketamine is simply “an opioid in disguise.” It likely means that opioid receptor activation is one necessary step in the chain of events that produces ketamine’s mood-lifting effects. The finding has clinical implications for people on naltrexone for alcohol or opioid use disorder who might also be candidates for ketamine treatment for depression: the two medications may work against each other. Researchers are still untangling which opioid receptor subtypes are involved and whether the effect depends on endorphin release or direct receptor binding by ketamine itself.
Opioid Antagonists and the Rebound Effect
If opioid drugs suppress the body’s natural endorphin output over time, can you do the opposite, briefly block the receptors and trick the body into making more? That’s the core idea behind low-dose naltrexone (LDN). At standard doses (50 mg), naltrexone is a straightforward opioid blocker used to treat addiction.13PubMed Central. Naltrexone: Not Just for Opioids Anymore At much lower doses, typically in the range of 1 to 5 mg, the blockade is brief and incomplete. The leading hypothesis is that this small, transient blockade prompts the body to compensate by upregulating both endogenous opioid production and receptor density, an “opioid rebound” effect that has been demonstrated repeatedly.14PubMed Central. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
In animal models, acute LDN treatment increased plasma levels of both beta-endorphin and a related peptide called opioid growth factor, and those increases were associated with improved neuronal recovery after stroke in diabetic mice.15PubMed. Acute Low Dose Naltrexone Increases β-Endorphin and Promotes Neuronal Recovery Following Hypoxia-Ischemic Stroke in Type-2 Diabetic Mice Multiple reports describe LDN’s second mode of action as this transient opioid receptor blockade that upregulates opioid signaling, leading to greater endogenous opioid production.16PubMed. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes LDN is being explored for conditions ranging from fibromyalgia to Crohn’s disease, though large-scale controlled trials remain scarce. The concept is intellectually appealing, but the clinical evidence is still developing, and LDN is not FDA-approved for any of these off-label uses.
Spicy Food and Capsaicin
Not every endorphin-altering substance comes in pill form. Capsaicin, the compound that makes chili peppers hot, can elevate beta-endorphin levels in cerebrospinal fluid, which may explain why eating very spicy food often produces a sense of mild euphoria alongside the burning sensation.17PubMed Central. The analgesic effect and neural mechanism of spicy food intake The mechanism starts with pain. Capsaicin activates pain-sensing neurons, and the brain responds by releasing endorphins to dampen the signal. Several theories attempt to explain why people develop a preference for foods that are, by any objective measure, painful. Among the leading explanations are the “thrill” of the sensation and physiological reinforcement associated with endorphin release triggered by the painful stimulus.18Food Quality and Preference. It hurts so good: oral irritation by spices and carbonated drinks and the underlying neural mechanisms
This also makes capsaicin a tool in pain research. Topical capsaicin creams are used clinically for nerve pain, and the endorphin component appears to play a role alongside the better-known mechanism of desensitizing local pain fibers. If you’ve ever noticed that a brutally hot meal left you feeling oddly calm afterward, that’s probably your endorphins talking.
The Placebo Effect Runs on Endorphins
One of the more fascinating entries on the list of things that alter endorphin activity isn’t a drug at all. Placebo analgesia, the pain relief people experience after receiving a treatment they believe is real but isn’t, is at least partly mediated by the body’s own opioid system. Early work showed that placebo reduces post-surgical pain compared with no treatment, and that the pain relief could be reversed by naloxone, an opioid blocker.19PubMed. Placebo and naloxone can alter post-surgical pain by separate mechanisms Subsequent experiments confirmed that a portion of the placebo response is blocked by opioid antagonists.20Pain. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia
More recent research has pushed this further. Even open-label placebos, where people are explicitly told they’re receiving a placebo, can produce pain relief that naloxone reverses.21PubMed. Open-label nondeceptive placebo analgesia is blocked by the opioid antagonist naloxone That finding is striking because it means the endorphin release doesn’t require deception. Just the ritual and expectation of treatment seem sufficient to trigger the body’s opioid machinery. This has real implications for how we think about pain management: every clinical encounter, including the act of being given a pill, activates endorphin pathways to some degree. It also means that when researchers test new painkillers against a placebo, part of what the placebo group is experiencing is genuine, measurable endorphin-driven analgesia rather than imagined improvement.
Exercise and the Blood-Brain Barrier Problem
Vigorous exercise is often cited as a “natural” way to boost endorphins. The data confirms that intense effort does raise plasma beta-endorphin levels, but there’s a catch that almost never makes it into the popular conversation. In trained endurance athletes, running at moderate intensity (up to about 80% of maximum capacity) did not produce any significant change in circulating beta-endorphin. Only when intensity crossed an anaerobic threshold, around 92% and above, did beta-endorphin and the related stress hormone ACTH rise dramatically, roughly tripling at 92% intensity and increasing more than fivefold at 98%.22Elsevier / Life Sciences. β-Endorphin and corticotropin release is dependent on a threshold intensity of running exercise in male endurance athletes
But here’s the problem researchers have wrestled with since the 1980s: measuring beta-endorphin in blood doesn’t necessarily tell you what’s happening in the brain. A large body of work has reproducibly demonstrated that blood beta-endorphin rises after various exercise challenges, yet these studies have failed to establish robust links between those peripheral levels and changes in mood or pain perception, the effects people attribute to the “runner’s high.” The quantitative relationship between endorphins in the blood and endorphins in the central nervous system remains unknown.23PubMed Central. Advocating neuroimaging studies of transmitter release in human physical exercise challenges studies Brain imaging with PET scans offers a more direct window and does show opioid receptor changes during exercise, but those studies are expensive and rare. The upshot is that the “endorphin rush” from running is probably real, but the confident blood-test numbers you see quoted in fitness magazines are measuring something several steps removed from what’s actually driving the feeling.
This measurement issue extends beyond exercise. Most research on how drugs affect endorphins in humans faces the same limitation: blood endorphin levels are easy to measure but may not reflect what’s happening behind the blood-brain barrier. Animal studies can measure brain tissue directly, and PET imaging can measure receptor occupancy in living humans, but the cheap and common approach of drawing blood and measuring beta-endorphin carries a serious interpretive asterisk. Keep that in mind whenever you see a headline claiming that a specific food, supplement, or activity “raises endorphins” by some impressive-sounding percentage.
Why Most “Endorphin-Boosting” Supplements Don’t Have Good Evidence
A quick search for “boost your endorphins naturally” will turn up lists recommending dark chocolate, acupuncture, meditation, laughter, UV light, and various herbal supplements. Some of these do have limited evidence behind them, usually from small studies measuring plasma beta-endorphin before and after an intervention. But those studies generally suffer from the same blood-versus-brain measurement problem described above, along with small sample sizes and inconsistent results across labs. The supplement industry in particular is fond of extrapolating wildly from a single rat study to a human health claim.
The interventions with the strongest evidence for engaging the endorphin system, beyond the drugs covered earlier, are intense physical exercise (with the caveats about intensity thresholds) and social bonding. The opioid system has been implicated in the warm feeling of social connection, and naltrexone can dampen the rewarding quality of social interactions in experimental settings. Massage, laughter, and music have all been linked to endorphin release in some studies, typically using the indirect proxy of pain tolerance as a stand-in for endorphin levels, since people with more endorphin activity tolerate experimentally induced pain for longer. These effects are real but modest, nothing like the magnitude of change produced by opioid drugs or even alcohol.
When Endorphin Changes Become a Clinical Problem
For most people, everyday fluctuations in endorphin activity go unnoticed. The clinical relevance emerges at the extremes. At one end, people with opioid use disorder have a measurably degraded endorphin system, with reduced receptor density and diminished endorphin production, that contributes to the protracted withdrawal syndrome many experience for months or even years after quitting. This endorphin deficit helps explain why the early months of sobriety are so bleak for many people and why medications like methadone and buprenorphine, which partially activate the mu receptor, remain first-line treatments for opioid addiction.
At the other end, certain rare genetic conditions result in overactive or underactive endorphin signaling from birth, altering pain sensitivity and stress responses in ways that can be medically significant. Some researchers have also explored whether chronically low endorphin tone might contribute to conditions like fibromyalgia and certain types of depression, though these links remain speculative and are difficult to study directly in humans given the measurement challenges. The endorphin system sits at a crossroads of pain, mood, reward, and social connection, which makes it fascinating to study and maddeningly difficult to manipulate in isolation. Every drug that touches it tends to touch several other systems at the same time, and the body’s compensatory responses ensure that the picture is never as simple as “more endorphins equals feeling better.”